Heidelberg Pharma AG
XETRA:HPHA

Watchlist Manager
Heidelberg Pharma AG Logo
Heidelberg Pharma AG
XETRA:HPHA
Watchlist
Price: 3.2 EUR 3.9% Market Closed
Market Cap: 149.7m EUR

Intrinsic Value

The intrinsic value of one HPHA stock under the Base Case scenario is 2.42 EUR. Compared to the current market price of 3.2 EUR, Heidelberg Pharma AG is Overvalued by 24%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

HPHA Intrinsic Value
2.42 EUR
Overvaluation 24%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Heidelberg Pharma AG

What is Valuation History?
Ask AI Assistant
What other research platforms think about HPHA?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is HPHA valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Heidelberg Pharma AG.

Explain Valuation
Compare HPHA to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about HPHA?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Heidelberg Pharma AG

Current Assets 41m
Cash & Short-Term Investments 22.9m
Receivables 1.5m
Other Current Assets 16.6m
Non-Current Assets 13.1m
PP&E 3.1m
Intangibles 8.8m
Other Non-Current Assets 1.2m
Current Liabilities 7m
Accounts Payable 5.7m
Other Current Liabilities 1.3m
Non-Current Liabilities 36.5m
Long-Term Debt 36.5m
Efficiency

Free Cash Flow Analysis
Heidelberg Pharma AG

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Heidelberg Pharma AG

Revenue
3m EUR
Cost of Revenue
-465.9k EUR
Gross Profit
2.6m EUR
Operating Expenses
-29.8m EUR
Operating Income
-27.2m EUR
Other Expenses
1m EUR
Net Income
-26.2m EUR
Fundamental Scores

HPHA Profitability Score
Profitability Due Diligence

Heidelberg Pharma AG's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
Exceptional Gross Margin
Strong 3Y Average Gross Margin
Gross Margin is Increasing
22/100
Profitability
Score

Heidelberg Pharma AG's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

HPHA Solvency Score
Solvency Due Diligence

Heidelberg Pharma AG's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Positive Net Debt
High D/E
31/100
Solvency
Score

Heidelberg Pharma AG's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HPHA Price Targets Summary
Heidelberg Pharma AG

Wall Street analysts forecast HPHA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HPHA is 5.61 EUR with a low forecast of 5.56 EUR and a high forecast of 5.78 EUR.

Lowest
Price Target
5.56 EUR
74% Upside
Average
Price Target
5.61 EUR
75% Upside
Highest
Price Target
5.78 EUR
80% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Heidelberg Pharma AG
does not pay dividends
Shareholder Yield

Current shareholder yield for HPHA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one HPHA stock?

The intrinsic value of one HPHA stock under the Base Case scenario is 2.42 EUR.

Is HPHA stock undervalued or overvalued?

Compared to the current market price of 3.2 EUR, Heidelberg Pharma AG is Overvalued by 24%.

Back to Top